TARIS® IS LEVERAGING ITS UNIQUE EXPERTISE IN BLADDER BIOLOGY TO DEVELOP NOVEL TREATMENT OPTIONS FOR BLADDER DISEASES.
TARIS® is advancing TAR-200 for the treatment of muscle invasive bladder cancer (MIBC). This program continuously administers the approved agent gemcitabine for multiple weeks. We believe that TAR-200 has the potential to harness both direct antitumor and immuno-oncologic activity without meaningful systemic drug exposure, yielding a powerful therapy and mitigating systemic side-effects.
MIBC: TARIS is advancing TAR-200 for the 40% or more of MIBC patients who do not receive potentially curative therapy (radical cystectomy or curative radiotherapy). TAR-200 has the unique potential to markedly improve survival and overall outcomes for these profoundly underserved patients.
MIBC Collaboration: In December 2017, TARIS and Bristol-Myers Squibb announced a clinical trial collaboration investigating TAR-200 in combination with Opdivo® (nivolumab). The Phase 1b trial will evaluate the combination in patients with MIBC who are scheduled for radical cystectomy.
TARIS® is advancing TAR-302 for the treatment of overactive bladder (OAB). We are developing a continuous local therapy for the management of OAB using trospium chloride, an approved agent. By dosing this drug directly to the bladder for an extended period, we believe that TAR-302 has the potential to offer substantially improved efficacy, while minimizing bothersome systemic side effects seen with oral administration of these types of agents. We believe this has the potential to be the best available therapy for patients unsatisfied with oral treatments.
Additional Areas of Focus
In addition to our lead programs in bladder cancer and overactive bladder, TARIS® continues to evaluate new products that may address additional areas of unmet need.